EMA confirms Roche's MabThera made at Vacaville site poses no health risk
The Pharma Letter
The review of MabThera was initiated after the unexpected detection of Leptospira licerasiae at an early stage (pre-harvest) of the manufacturing process of rituximab in bioreactors at Vacaville. The contaminant was not detected at later stages of ...
EMA okays MabThera after contamination at Roche

all 2 news articles »